EUVIMEDEUVIMED entdecken
Crossref

2187-LB: Clinical, Functional, and Therapeutic Implications of a Novel Monogenic Obesity Trait

KATHRIN LANDGRAF, ERIC WENZEL, THOMAS REINEHR, ALEXANDER JAIS, MATTHIAS BLÜHER, MARTIN WABITSCH, ANTJE KÖRNER

Diabetes · 20.06.2025 · 74 (Supplement_1)

DOI: 10.2337/db25-2187-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 20.06.2025. Verfasst von KATHRIN LANDGRAF und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: We recently identified a novel human monogenic obesity trait caused by ubiquitous ectopic expression of agouti-signalling protein (ASIP) (Kempf E, 2022). We here screened for new patients and thoroughly characterized the clinical phenotype.

Methods

To gain mechanistic insights, we established and characterized knock-in (ki) mice with human ASIP expression for obesity, metabolic parameters, food intake, energy expenditure and locomotor activity, and tested the responsiveness to treatment with the MC4R agonist setmelanotide.

Results

We identified altogether 20 patients with the identical breakpoint mutation, who consistently exhibited extreme obesity from early childhood and a height SDS > 50th percentile. Red(dish) hair was common (particularly during childhood). Hyperphagia was more inconsistently reported. Interestingly resting metabolic rates were significantly lower compared to age-matched peers. Concordantly, we found lower mitochondrial respiration in primary cells and iPSC derived hypothalamic-like neurons of the ASIP mutation index patient. Similar to the patients, heterozygous ki/wt mice developed early and sustained obesity and increased body length compared to wild type control mice with an increase in fat mass, accompanied by glucose intolerance and insulin resistance. Metabolic phenotyping using indirect calorimetry revealed a modest increase in food intake, decreased locomotor activity but no alterations in energy expenditure. Treatment with setmelanotide led to a significant reduction in the bodyweight of ki/wt mice and was associated with an inhibition of food intake.

Conclusion

The identification of 20 patients indicates a relatively high frequency of the new monogenic trait with the implication to rethink screening algorithms. Patient phenotypes mimick the agouti-mouse phenotype. Our findings from the humanized mouse model indicate that the obesity phenotype is caused by ectopic ASIP and might be treatable with the MC4R agonist setmelanotide. Disclosure K. Landgraf: None. E. Wenzel: None. T. Reinehr: Advisory Panel; Novo Nordisk, Merck & Co., Inc. A. Jais: None. M. Blüher: Advisory Panel; AstraZeneca. Speaker's Bureau; Amgen Inc. Advisory Panel; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim. Speaker's Bureau; Daiichi Sankyo. Advisory Panel; Eli Lilly and Company, Novo Nordisk, Nestlé Health Science, Sanofi-Aventis Deutschland GmbH. M. Wabitsch: Consultant; Novo Nordisk, Nestlé Health Science, Chiesi Farmaceutici, Rhythm Pharmaceuticals, Inc, Abbott. Other Relationship; Merck Healthcare Germany, Novo Nordisk, Rhythm Pharmaceuticals, Inc, Chiesi Farmaceutici, SYNLAB, Abbott, Sandoz, InfectoPharm, Mediagnost, Ascendis Pharma A/S, Hexal AG, Novo Nordisk, Merck Healthcare Germany, Abbott, Sandoz, SYNLAB. Board Member; Chiesi Pharmaceutici, Rhythm Pharmaceuticals, Inc, Novo Nordisk, Nestlé Health Science, Abbott. A. Körner: Advisory Panel; Novo Nordisk. Speaker's Bureau; Merck & Co., Inc, Novo Nordisk. Funding German Research Foundation (DFG), SFB1052/CRC1052 ( 209933838)

Zitieren

APA

LANDGRAF, K., WENZEL, E., REINEHR, T., JAIS, A., BLÜHER, M., WABITSCH, M., & KÖRNER, A. (2025). 2187-LB: Clinical, Functional, and Therapeutic Implications of a Novel Monogenic Obesity Trait. Diabetes, 74(Supplement_1). https://doi.org/10.2337/db25-2187-lb

Vancouver

LANDGRAF K, WENZEL E, REINEHR T, JAIS A, BLÜHER M, WABITSCH M, et al. 2187-LB: Clinical, Functional, and Therapeutic Implications of a Novel Monogenic Obesity Trait. Diabetes. 2025;74(Supplement_1). doi:10.2337/db25-2187-lb

BibTeX
@article{LANDGRAF2025,
  author = {LANDGRAF, KATHRIN and WENZEL, ERIC and REINEHR, THOMAS and JAIS, ALEXANDER and BLÜHER, MATTHIAS and WABITSCH, MARTIN and KÖRNER, ANTJE},
  title = {2187-LB: Clinical, Functional, and Therapeutic Implications of a Novel Monogenic Obesity Trait},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {Supplement_1},
  doi = {10.2337/db25-2187-lb}
}
Kostenlos starten →